How to buy Freeline Therapeutics stock | $11

Freeline Therapeutics Holdings plc is a biotechnology business based in the US. Freeline Therapeutics shares (FRLN) are listed on the NASDAQ and all prices are listed in US Dollars. Freeline Therapeutics employs 236 staff and has a market cap (total outstanding shares value) of 0.00.

Freeline Therapeutics stock price (NASDAQ: FRLN)

Use our graph to track the performance of FRLN stocks over time.

Freeline Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-28.

Latest market close	$11.00
52-week range	$4.26 - $21.69
50-day moving average	$7.97
200-day moving average	$12.07
Wall St. target price	$24.88
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Freeline Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Freeline Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Freeline Therapeutics Holdings plc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Freeline Therapeutics price performance over time

Historical closes compared with the close of $11 from 2021-05-28

1 week (2021-07-23)	N/A
1 month (2021-07-02)	33.98%
3 months (2021-05-03)	-3.17%
6 months (2021-01-30)	N/A

1 year (2020-07-30)	N/A
2 years (2019-07-30)	N/A
3 years (2018-07-30)	N/A
5 years (2016-07-30)	N/A

Freeline Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-34.28%
Return on equity TTM	-75.28%
Profit margin	0%
Book value	$6.12
Market capitalisation	$172.1 million

TTM: trailing 12 months

Shorting Freeline Therapeutics shares

There are currently 34,363 Freeline Therapeutics shares held short by investors – that's known as Freeline Therapeutics's "short interest". This figure is 37.4% down from 54,852 last month.

There are a few different ways that this level of interest in shorting Freeline Therapeutics shares can be evaluated.

Freeline Therapeutics's "short interest ratio" (SIR)

Freeline Therapeutics's "short interest ratio" (SIR) is the quantity of Freeline Therapeutics shares currently shorted divided by the average quantity of Freeline Therapeutics shares traded daily (recently around 33041.346153846). Freeline Therapeutics's SIR currently stands at 1.04. In other words for every 100,000 Freeline Therapeutics shares traded daily on the market, roughly 1040 shares are currently held short.

However Freeline Therapeutics's short interest can also be evaluated against the total number of Freeline Therapeutics shares, or, against the total number of tradable Freeline Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Freeline Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Freeline Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.0028% of the tradable shares (for every 100,000 tradable Freeline Therapeutics shares, roughly 3 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Freeline Therapeutics.

Find out more about how you can short Freeline Therapeutics stock.

Freeline Therapeutics share dividends

We're not expecting Freeline Therapeutics to pay a dividend over the next 12 months.

Freeline Therapeutics overview

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom. .

Frequently asked questions

What percentage of Freeline Therapeutics is owned by insiders or institutions?
Currently 8.23% of Freeline Therapeutics shares are held by insiders and 33.84% by institutions. How many people work for Freeline Therapeutics?
Latest data suggests 236 work at Freeline Therapeutics. When does the fiscal year end for Freeline Therapeutics?
Freeline Therapeutics's fiscal year ends in December. Where is Freeline Therapeutics based?
Freeline Therapeutics's address is: Stevenage Bioscience Catalyst, Stevenage, United Kingdom, SG1 2FX What is Freeline Therapeutics's ISIN number?
Freeline Therapeutics's international securities identification number is: US35655L1070